Buchumschlag

EGFR and PI3K pathway activities might guide drug repurposing in HPV-negative head and neck cancers

carcinomas (HNSCC), their impact on oncogenic signaling and cancer drug sensitivities remains elusive. To determine their consequences on the transcriptional network, pathway activities of EGFR, PI3K and 12 additional oncogenic pathways were inferred in 498 HNSCC samples of The Cancer Genome Atlas u...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Mock, Andreas (VerfasserIn) , Plath, Michaela (VerfasserIn) , Moratin, Julius (VerfasserIn) , Tapken, Maria Johanna (VerfasserIn) , Jäger, Dirk (VerfasserIn) , Krauß, Jürgen (VerfasserIn) , Fröhling, Stefan (VerfasserIn) , Heß, Jochen (VerfasserIn) , Plath, Karim (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 11 June 2021
In: Frontiers in oncology
Year: 2021, Jahrgang: 11
ISSN:2234-943X
DOI:10.3389/fonc.2021.678966
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.3389/fonc.2021.678966
Verlag, kostenfrei: https://www.frontiersin.org/articles/10.3389/fonc.2021.678966/full
Volltext
Verfasserangaben:Andreas Mock, Michaela Plath, Julius Moratin, Maria Johanna Tapken, Dirk Jäger, Jürgen Krauss, Stefan Fröhling, Jochen Hess and Karim Zaoui
Beschreibung
Zusammenfassung:carcinomas (HNSCC), their impact on oncogenic signaling and cancer drug sensitivities remains elusive. To determine their consequences on the transcriptional network, pathway activities of EGFR, PI3K and 12 additional oncogenic pathways were inferred in 498 HNSCC samples of The Cancer Genome Atlas using PROGENy. More than half of HPV-negative HNSCC showed a pathway activation in EGFR or PI3K. An amplification in EGFR and a mutation in PI3KCA resulted in a significantly higher activity of the respective pathway (p=0.017 and p=0.007). Interestingly, both pathway activations could only be explained by genetic alterations in less than 25% of cases indicating additional molecular events involved in the downstream signaling. Suitable in vitro pathway models could be identified in a published drug screen of 45 HPV-negative HNSCC cell lines. An active EGFR pathway was predictive for the response to the PI3K inhibitor buparlisib (p=6.36E-03) and an inactive EGFR and PI3K pathway was associated with efficacy of the BCL inhibitor navitoclax (p=9.26E-03). In addition an inactive PI3K pathway correlated with a response to multiple HDAC inhibitors. These findings require validation in preclinical models and clinical studies.
Beschreibung:Gesehen am 09.07.2021
Beschreibung:Online Resource
ISSN:2234-943X
DOI:10.3389/fonc.2021.678966

Ähnliche Einträge